U.S. health insurance sector, Cigna and Humana are reportedly in talks for a merger exceeding $60 billion. However, industry observers predict that the proposed deal will undoubtedly face stringent antitrust scrutiny, marking a potential challenge for the two major health insurers.
The discussions between Cigna and Humana come six years after regulatory obstacles thwarted previous attempts to consolidate the health insurance industry. In 2017, U.S. courts upheld antitrust challenges, prompting Cigna to abandon a $48 billion deal to acquire Anthem, now rebranded as Elevance Health. The legal setback also led to Aetna, now under the ownership of pharmacy chain operator CVS Health, abandoning a $37 billion deal to acquire Humana.
According to a source familiar with the matter, Cigna and Humana are exploring a stock-and-cash deal, with the potential agreement expected to be finalized by the end of the year. The Wall Street Journal first reported on the potential merger, signaling a significant development in the industry. While Humana declined to comment on the matter, Cigna did not respond to requests for clarification.
Read more: Report: Health Insurance Firms Humana and Cigna in Merger Talks
The prospective merger is expected to draw intense antitrust scrutiny due to the substantial market consolidation it would entail. If successful, the combined entity would boast a formidable scale, allowing it to compete more effectively against larger U.S. health insurance players such as UnitedHealth Group and CVS Health.
Cigna and Humana, with market values of $77 billion and $59 billion, respectively, currently have limited business overlap, primarily concentrated in Medicare plans for older Americans. Notably, Humana’s Medicare business significantly outpaces Cigna’s in both size and profitability. Earlier this month, Reuters reported that Cigna was exploring the sale of its Medicare Advantage operations, aiming to enhance investor confidence following disappointing performance.
Industry experts suggest that divesting from Medicare Advantage could potentially increase the likelihood of regulatory approval for the merger, as it would mitigate concerns over reduced competition in specific market segments. Nonetheless, the sheer size and impact of the proposed merger are expected to attract close scrutiny from antitrust authorities.
Source: WSJ
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI